Loading...

On-Demand: The Hitchhiker’s Guide to CGTx in 2023

2023-01-31T16:48:49+00:00Events, Thought Leadership|

Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.

Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).

(more…)

White Paper: Achieving Launch Excellence: A Novel Data- and Analytics-Informed Approach

2023-01-21T00:56:23+00:00Thought Leadership|

Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights.

Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.

DOWNLOAD THE WHITEPAPER HERE!

Prescription Drug Inflation Rebates: The Inflation Reduction Act Impact Just Around The Corner

2023-01-20T17:36:40+00:00Thought Leadership|

More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.

READ THE ARTICLE HERE!

Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts

2023-01-20T16:40:37+00:00Events, Thought Leadership|

Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.

  • Assessing commercial viability
  • Developing clinical trial design and evidence-generation strategy
  • Planning for launch preparedness

Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.

CLICK HERE to read the full article

Collaboration is Needed Among Stakeholders for Genetic Tests to be Beneficial

2023-01-19T14:36:43+00:00Thought Leadership|

More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.

READ THE ARTICLE HERE!

40 Under 40: Ashwin Athri and Isabella Sergio

2023-01-19T14:07:59+00:00Events, Thought Leadership|

We’re excited to announce that two of our Precision colleagues have been named to MM+M’s 40 Under 40 this year! Congratulations to Ashwin Athri, EVP, Managing Director, PRECISIONxtract, and Isabella Sergio, EVP, Managing Director, PRECISIONvalue. Now in its fourth year, 40 Under 40 honors the industry’s best-regarded young talent. We look forward to celebrating with Ashwin and Isabella, and all the other honorees, on February 16.

Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome

2023-01-19T12:27:15+00:00Thought Leadership|

Congratulations to Precision’s Iver Jensen for his contributions to “Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome,” a study recently published in the Journal of Pediatric Pharmacology and Therapeutics. The study is the first cost-consequence analysis cost-consequence analysis comparing the clinical and health economic outcomes in newborns with RDS when using selective early surfactant treatment vs standard surfactant administration in the United States. Read the study here:

READ THE STUDY HERE!

Load More Posts